|Name||(3R,4R)-1-Benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride/Tofacitinib Citrate Intermediates CAS 1062580-52-2|
(3R,4R)-1-Benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride ;(3R,4R)-rel-1-Benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride ;
cis-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride ;
(3R,4R)-1-Benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride CAS 1062580-52-2 appears to be white powder. It can be used as intermediates for Tofacitinib. Tofacitinib CAS 477600-75-2 is an orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation.
(3R,4R)-1-Benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride CAS 1062580-52-2 has a molecular formula of C14H24Cl2N2 and a molecular weight of 291.26.
(3R,4R)-1-Benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride CAS 1062580-52-2 could be supplied in commercial size with competitive price.